Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
This is a prospective, Phase 1-2, single center study in a total of 100 subjects with Neuroendocrine Tumors (NETs). Study participants will receive a one-time administration of 68Ga-DOTATATE and undergo a PET/CT imaging study, to investigate its suitability as a PET imaging agent for NETs.
Epistemonikos ID: 17ae74d56d5f2f1c42f3bf5e1700872530624d4d
First added on: May 11, 2024